Spruce Biosciences (SPRB) announced that the FDA has granted breakthrough therapy designation to tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB: